

Appendix

Manuscript Title: Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient-reported outcome system for vaccine safety remote monitoring

Journal: Influenza and other respiratory viruses

Authors: Gaël Dos Santos¹, Tamara Eckermann², Xavier Martínez- Gómez³, Jose Parra¹, Ugo Nwoji⁴, Ignacio Salamanca de la Cueva⁵

Affiliations:

¹ GSK, Wavre, Belgium

² Hausarztpraxis Heimeranplatz, Munich, Germany

³ Hospital Universitari Vall d'Hebron, Barcelona, Spain

⁴ GSK, Rockville, MD, USA

⁵ Instituto Hispalense de Pediatría, Sevilla, Spain

Corresponding author: Gael Dos Santos

GSK, 20 Fleming Avenue, 1300 Wavre, Belgium

Email: gael.x.dos-santos@gsk.com

Telephone: +32 1085 9141

Table S1. Vaccines co-administered with GSK's IIV4

Co-administered vaccination class†	Germany N=422		Spain N=555		Total N-977	
	n	%	n	%	n	%
Any	48	11.4	61	11.0	109	11.2
Other viral (i.e., COVID-19)	46	10.9	1	0.2	47	4.8
Pneumococcal			31	5.6	31	3.2
Hepatitis			25	4.5	25	2.6
Papillomavirus			6	1.1	6	0.6
Meningococcal			5	0.9	5	0.5
Measles			4	0.7	4	0.4
Tetanus			3	0.5	3	0.3
Varicella zoster	1	0.2	2	0.4	3	0.3
Hemophilus influenzae b			2	0.4	2	0.2
Bacterial and viral, combined	1	0.2			1	0.1
Pertussis			1	0.2	1	0.1

COVID-19: coronavirus disease 2019; IIV4: inactivated quadrivalent seasonal influenza vaccine; N, n: Total number, number in subcategory

†Vaccination classes coded using World Health Organization Drug Dictionary